{"id":"https://openalex.org/W7204692989","doi":"https://doi.org/10.17605/osf.io/cyfsg","title":"Exposure, Not Route: Cardiovascular Pharmacology of Oral versus Injectable GLP-1 Receptor Agonists","display_name":"Exposure, Not Route: Cardiovascular Pharmacology of Oral versus Injectable GLP-1 Receptor Agonists","publication_year":2026,"publication_date":"2026-08-30","ids":{"openalex":"https://openalex.org/W7204692989","doi":"https://doi.org/10.17605/osf.io/cyfsg"},"language":"en","primary_location":{"id":"pmh:doi:10.17605/osf.io/cyfsg","doi":null,"is_oa":true,"landing_page_url":"https://osf.io/cyfsg","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"StudyRegistration"},"volume":null,"type":"preprint","is_traditional":true,"indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://osf.io/cyfsg","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5144226672","display_name":"Jeel Padaria","orcid":"https://orcid.org/0009-0004-6509-4172","observed_orcids":["https://orcid.org/0009-0004-6509-4172"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeel Padaria","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0004-6509-4172","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5144241165","display_name":"Abiya Ahad","orcid":"https://orcid.org/0009-0008-5767-0722","observed_orcids":["https://orcid.org/0009-0008-5767-0722"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Abiya Ahad","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5041218096","display_name":"Darshan Hullon","orcid":"https://orcid.org/0009-0001-9163-1881","observed_orcids":["https://orcid.org/0009-0001-9163-1881"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Darshan Hullon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9160000085830688},{"id":"https://openalex.org/keywords/oral-semaglutide","display_name":"oral semaglutide","score":0.8920000195503235},{"id":"https://openalex.org/keywords/orforglipron","display_name":"orforglipron","score":0.9950000047683716},{"id":"https://openalex.org/keywords/route-of-administration","display_name":"route of administration","score":0.9539999961853027},{"id":"https://openalex.org/keywords/drug-exposure","display_name":"drug exposure","score":0.7120000123977661},{"id":"https://openalex.org/keywords/cardiovascular-safety","display_name":"cardiovascular safety","score":0.7319999933242798},{"id":"https://openalex.org/keywords/major-adverse-cardiovascular-events","display_name":"major adverse cardiovascular events","score":0.8799999952316284},{"id":"https://openalex.org/keywords/heart-failure-with-preserved-ejection-fraction","display_name":"heart failure with preserved ejection fraction","score":0.9340000152587891},{"id":"https://openalex.org/keywords/renal-outcomes","display_name":"renal outcomes","score":0.6690000295639038},{"id":"https://openalex.org/keywords/heart-rate","display_name":"heart rate","score":0.6119999885559082},{"id":"https://openalex.org/keywords/blood-pressure","display_name":"blood pressure","score":0.9980000257492065},{"id":"https://openalex.org/keywords/intestinal-barrier-function","display_name":"intestinal barrier function","score":0.5849999785423279},{"id":"https://openalex.org/keywords/endotoxin-translocation","display_name":"endotoxin translocation","score":0.878000020980835},{"id":"https://openalex.org/keywords/absorption-enhancers","display_name":"absorption enhancers","score":0.597000002861023},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.421999990940094}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8367000222206116},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5353000164031982},{"id":"https://openalex.org/C2909862629","wikidata":"https://www.wikidata.org/wiki/Q27261089","display_name":"Semaglutide","level":5,"score":0.4957999885082245},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4812000095844269},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.46790000796318054},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.46149998903274536},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.41929998993873596},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.41200000047683716},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.39149999618530273},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.38850000500679016},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.383899986743927},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.30300000309944153},{"id":"https://openalex.org/C3020000205","wikidata":"https://www.wikidata.org/wiki/Q2412849","display_name":"Narrative review","level":2,"score":0.28600001335144043},{"id":"https://openalex.org/C63433958","wikidata":"https://www.wikidata.org/wiki/Q1774688","display_name":"Clinical pharmacology","level":2,"score":0.2676999866962433},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2651999890804291},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.2612999975681305},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.2583000063896179},{"id":"https://openalex.org/C120770815","wikidata":"https://www.wikidata.org/wiki/Q14859627","display_name":"Vasodilation","level":2,"score":0.25769999623298645},{"id":"https://openalex.org/C14527384","wikidata":"https://www.wikidata.org/wiki/Q4693403","display_name":"Agonism","level":3,"score":0.25119999051094055}],"mesh":[],"locations_count":2,"locations":[{"id":"pmh:doi:10.17605/osf.io/cyfsg","doi":null,"is_oa":true,"landing_page_url":"https://osf.io/cyfsg","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"StudyRegistration"},{"id":"doi:10.17605/osf.io/cyfsg","doi":"https://doi.org/10.17605/osf.io/cyfsg","is_oa":true,"landing_page_url":"https://doi.org/10.17605/osf.io/cyfsg","pdf_url":null,"source":{"id":"https://openalex.org/S7407050956","display_name":"Open Science Framework","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2799848540","host_organization_name":"Center for Open Science","host_organization_lineage":["https://openalex.org/I2799848540"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"StudyRegistration"}],"best_oa_location":{"id":"pmh:doi:10.17605/osf.io/cyfsg","doi":null,"is_oa":true,"landing_page_url":"https://osf.io/cyfsg","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"StudyRegistration"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7204592113","https://openalex.org/W3131762509","https://openalex.org/W2969705410","https://openalex.org/W7154685041","https://openalex.org/W7219905082","https://openalex.org/W3199831757","https://openalex.org/W3198399789","https://openalex.org/W2903342525","https://openalex.org/W7134114532","https://openalex.org/W2955610174"],"abstract_inverted_index":{"This":[0,256],"research":[1,407],"project":[2,449],"is":[3,65,112,171,228,259,350,376],"a":[4,290,351,406],"narrative":[5],"review":[6,33,64,87,134,184,214,234,280,349,375,403],"examining":[7],"whether":[8,90,236,355,453,468],"the":[9,35,50,68,71,103,187,190,196,204,213,216,221,242,262,295,311,348,364,399,448],"cardiovascular":[10,72,104,139,144,147,165,254,368,388,419,465],"effects":[11,73,219,264,471],"of":[12,22,62,74,168,189,206,212,220,265,313,347,354,367,425,441],"glucagon-like":[13],"peptide-1":[14],"receptor":[15,56,76,99,267,372],"agonists":[16],"(GLP-1RAs)":[17],"differ":[18],"according":[19],"to":[20,66,114,195,378,451],"route":[21,84,217,362,461],"administration,":[23],"with":[24,107,151,230,285],"particular":[25],"emphasis":[26],"on":[27,269],"oral":[28,47,54,92,176,199,231,315,382,414,454],"versus":[29,415],"injectable":[30,40,108,169,201,384,416],"therapy.":[31,109],"The":[32,59,86,133,183,233,279,344,374,402],"addresses":[34],"emerging":[36],"transition":[37],"from":[38,163,175,370,393],"predominantly":[39],"GLP-1RAs":[41,170],"toward":[42],"orally":[43],"administered":[44],"agents,":[45],"including":[46,120,141,412],"semaglutide":[48,177],"and":[49,97,118,131,159,181,192,200,203,253,276,303,318,328,338,383,397,420,428,436,439,444],"newer":[51],"non":[52],"peptide":[53],"GLP-1":[55,75,266,371],"agonist":[57],"orforglipron.":[58],"primary":[60],"purpose":[61],"this":[63,307,342],"evaluate":[67],"hypothesis":[69],"that":[70,94],"agonism":[77,268],"are":[78],"primarily":[79,457],"exposure-dependent":[80],"rather":[81,360],"than":[82,361],"intrinsically":[83],"dependent.":[85],"therefore":[88],"examines":[89,186],"an":[91,324,458,463],"GLP-1RA":[93,316],"achieves":[95],"adequate":[96],"reliable":[98],"exposure":[100,202,333,359,435],"should":[101],"reproduce":[102],"benefits":[105],"observed":[106],"Particular":[110],"attention":[111],"given":[113],"differences":[115],"in":[116,306,321,341],"pharmacokinetics":[117],"pharmacodynamics,":[119],"bioavailability,":[121],"dose-to-dose":[122],"variability,":[123,334],"dosing":[124],"interval,":[125],"peak-to-trough":[126],"dynamics,":[127],"achieved":[128,434],"exposure,":[129],"titration,":[130],"adherence.":[132],"synthesizes":[135],"evidence":[136,174,326,357,392],"across":[137],"several":[138],"domains,":[140],"major":[142,164],"adverse":[143],"events,":[145],"atherosclerotic":[146],"disease,":[148],"heart":[149,157,283,426],"failure":[150,284],"preserved":[152,286],"ejection":[153,287],"fraction,":[154],"renal":[155],"outcomes,":[156],"rate,":[158],"blood":[160,429],"pressure.":[161],"Evidence":[162],"outcome":[166,317,346],"trials":[167,320],"considered":[172],"alongside":[173,261],"trials,":[178],"particularly":[179],"PIONEER-6":[180],"SOUL.":[182],"also":[185,404],"relevance":[188],"OASIS":[191],"STEP":[193],"programmes":[194],"relationship":[197],"between":[198],"magnitude":[205],"weight":[207,437],"loss.":[208],"A":[209],"specific":[210,218,330],"component":[211],"evaluates":[215],"absorption":[222],"enhancer":[223,243],"sodium":[224],"N-(8-[2-hydroxybenzoyl]amino)caprylate":[225],"(SNAC),":[226],"which":[227],"co-administered":[229],"semaglutide.":[232],"considers":[235,282],"transient":[237],"epithelial":[238],"permeability":[239,443],"induced":[240],"by":[241,301],"could":[244],"theoretically":[245],"influence":[246],"intestinal":[247,270,335,442],"barrier":[248,271,336],"function,":[249,337],"endotoxin":[250,274],"translocation,":[251],"inflammation,":[252],"risk.":[255],"potential":[257],"mechanism":[258],"assessed":[260],"counter-regulatory":[263],"integrity,":[272],"chylomicron-mediated":[273],"trafficking,":[275],"systemic":[277],"inflammation.":[278],"further":[281],"fraction":[288],"as":[289,323,363],"distinct":[291],"clinical":[292],"domain":[293],"because":[294],"gastrointestinal":[296],"tract":[297],"may":[298],"be":[299],"affected":[300],"congestion":[302],"altered":[304],"physiology":[305],"population.":[308],"It":[309],"identifies":[310],"absence":[312],"dedicated":[314],"functional":[319],"HFpEF":[322,421],"important":[325],"gap":[327],"proposes":[329,405],"hypotheses":[331],"concerning":[332],"inflammatory":[339],"markers":[340],"setting.":[343],"expected":[345,377],"structured":[352],"assessment":[353,424],"current":[356],"supports":[358],"principal":[365],"determinant":[366],"benefit":[369],"agonism.":[373],"identify":[379],"areas":[380],"where":[381],"therapies":[385],"demonstrate":[386],"concordant":[387],"effects,":[389],"distinguish":[390],"established":[391,464],"cross":[394],"trial":[395],"inference,":[396],"define":[398],"remaining":[400],"uncertainties.":[401],"agenda":[408],"for":[409,462],"future":[410],"studies,":[411],"exposure-matched":[413],"comparisons,":[417],"domain-specific":[418],"endpoints,":[422],"prospective":[423],"rate":[427],"pressure,":[430],"mediation":[431],"analyses":[432],"incorporating":[433],"loss,":[438],"measurement":[440],"endotoxemia":[445],"markers.":[446],"Overall,":[447],"aims":[450],"clarify":[452],"administration":[455],"represents":[456],"alternative":[459],"delivery":[460],"pharmacology":[466],"or":[467],"route-specific":[469],"pharmacological":[470],"require":[472],"independent":[473],"evaluation.":[474]},"counts_by_year":[],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2026-08-31T00:00:00"}